Castellan Group Invests $2.11 Million in Thermo Fisher Scientific Inc. $TMO

Key Points

• Castellan Group bought a new position in Thermo Fisher (NYSE:TMO) of 3,637 shares in Q4, valued at approximately $2.11 million.
• CEO Marc N. Casper sold 5,000 shares for about $2.56 million on March 4 and EVP Gianluca Pettiti sold 400 shares, leaving insiders with just 0.33% ownership while institutional investors hold roughly 89.23% of the stock.
• Analysts have a consensus "Moderate Buy" with an average price target of $632.50; Thermo Fisher recently beat Q4 EPS/revenue estimates (EPS $6.57; revenue $12.22B) and raised its quarterly dividend to $0.47 (annualized $1.88, ~0.4% yield).

Castellan Group bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,637 shares of the medical research company's stock, valued at approximately $2,107,000.

Other hedge funds have also modified their holdings of the company. Cornerstone Investment Partners LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $41,393,000. Weaver Capital Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $506,000. Mackenzie Financial Corp increased its holdings in Thermo Fisher Scientific by 29.4% during the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company's stock valued at $134,130,000 after purchasing an additional 62,790 shares in the last quarter. VELA Investment Management LLC boosted its position in Thermo Fisher Scientific by 65.5% in the 3rd quarter. VELA Investment Management LLC now owns 9,305 shares of the medical research company's stock valued at $4,513,000 after buying an additional 3,683 shares during the last quarter. Finally, NEOS Investment Management LLC boosted its position in Thermo Fisher Scientific by 28.6% in the 3rd quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company's stock valued at $24,913,000 after buying an additional 11,415 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company's stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the sale, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. The trade was a 1.89% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on TMO shares. Robert W. Baird set a $653.00 price objective on Thermo Fisher Scientific in a research report on Friday, January 30th. Stifel Nicolaus increased their price objective on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a "buy" rating in a research report on Friday, January 9th. Evercore reiterated an "outperform" rating and issued a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. Finally, TD Cowen decreased their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating on the stock in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $632.50.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $496.34 on Monday. The company has a market capitalization of $184.45 billion, a PE ratio of 27.98, a PEG ratio of 2.66 and a beta of 0.97. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The stock's fifty day simple moving average is $505.33 and its 200 day simple moving average is $549.42.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm's revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the business posted $6.10 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Friday, March 13th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.60%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.